BSX-Spin-out Navilys Charts New Course

Article preview from IN VIVO - September 2008

Find out how Navilyst Medical, one of several properties recently spun out of Boston Scientific, has designs on growing into a large player in the venous access and fluid management industries.

Article preview from IN VIVO - September 2008

Navilyst Medical Inc. isn't in the business of making headlines. Company management left the front pages behind when private equity firm Avista Capital Partners acquired the venous access and fluid management businesses from constant newsmaker Boston Scientific Corp. back in February. Since the spin out, Navilyst executives have melded the two businesses into a single company with designs on becoming "the first choice" for venous access and fluid management devices.

Unlike Boston Scientific, Navilyst won't be swinging for the fences with high profile acquisitions of technology-heavy, high-growth businesses like Guidant Corp. Instead, President David McClellan, a former Boston Scientific executive, sees Navilyst following a quieter and safer path by introducing a slow but steady stream of bread-and-butter, 510(k)-track devices and equipment serving the comparatively slow-growth industries of venous access and fluid management, which both play supportive roles in the more high-profile stent and cardiac catheterization markets.

Purchase this 1003-word article as a PDF online for just $85 and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.

Companies mentioned in this article:

AngioDynamics
Boston Scientific
CR Bard
Merit Medical Systems
Pfizer

IN VIVO is the premier strategic business resource for the biopharma, medtech, and diagnostics industries.